Invasight Overview
- Year Founded
-
2019
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
- Investors
-
1
Invasight General Information
Description
Operator of a biotechnology company intended to accelerate the development of targeted therapies for invasive cancers. The company's therapies are designed to specifically target the proteins that are involved in cancer cell invasion, which can help to reduce the side effects that are often associated with traditional cancer treatments, thereby enabling cancer patients to access an effective and safe treatment option.
Contact Information
Website
www.invasight.comCorporate Office
- Balgrist campus
- Lengghalde 5
- 8008 Zurich
- Switzerland
Corporate Office
- Balgrist campus
- Lengghalde 5
- 8008 Zurich
- Switzerland
Invasight Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 24-Oct-2025 | Completed | Out of Business | |||
| 5. Early Stage VC | Cancelled | Pre-Clinical Trials | ||||
| 4. Seed Round | 07-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 05-Jun-2019 | Completed | Startup | |||
| 2. Grant | 19-Feb-2019 | $10K | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2019 | Completed | Startup |
Invasight Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 100,000 | $0.010245 | $1.02 | $1.02 | 1x | $1.02 | 0.57% |
Invasight Comparisons
Industry
Financing
Details
Invasight Competitors (3)
One of Invasight’s 3 competitors is Repare Therapeutics, a Formerly VC-backed company based in Saint-Laurent, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Repare Therapeutics | Formerly VC-backed | Saint-Laurent, Canada | ||||
| MUVON Therapeutics | Venture Capital-Backed | Zurich, Switzerland | ||||
| Syros Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Invasight Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Invasight Patents
Invasight Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023105008-A1 | Small-molecule inhibitors of the frs2-fgfr interaction | Inactive | 08-Dec-2021 |
Invasight Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Invasight Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of Zürich | University |
Invasight FAQs
-
When was Invasight founded?
Invasight was founded in 2019.
-
Where is Invasight headquartered?
Invasight is headquartered in Zurich, Switzerland.
-
What is the size of Invasight?
Invasight has 6 total employees.
-
What industry is Invasight in?
Invasight’s primary industry is Drug Discovery.
-
Is Invasight a private or public company?
Invasight is a Private company.
-
What is Invasight’s current revenue?
The current revenue for Invasight is .
-
How much funding has Invasight raised over time?
Invasight has raised $4.65M.
-
Who are Invasight’s investors?
University of Zürich has invested in Invasight.
-
Who are Invasight’s competitors?
Repare Therapeutics, MUVON Therapeutics, and Syros Pharmaceuticals are competitors of Invasight.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
